EGFR and neoplasm: After binding of these TAA-Vδ2hi-lo bsVHH and TAA-Vδ2hi-lo bsVHH-Fc molecules to the TAA expressing tumor cells was confirmed (Figure 2D), the antitumor effector functions of these molecules were evaluated in co-cultures of Vγ9Vδ2 T-cells and tumor cells expressing the respective TAAs (i.e. SW480 (EGFR+), 22Rv1 (PSMA+) or MM.1s.CD1d (CD1d+)).